Glenbrook Capital Management Acquires 5,685 Shares of Senestech (NASDAQ:SNES) Stock

Senestech, Inc. (NASDAQ:SNES) major shareholder Glenbrook Capital Management bought 5,685 shares of the company’s stock in a transaction on Wednesday, February 4th. The stock was bought at an average price of $1.82 per share, for a total transaction of $10,346.70. Following the completion of the purchase, the insider directly owned 599,470 shares in the company, valued at approximately $1,091,035.40. This represents a 0.96% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Glenbrook Capital Management also recently made the following trade(s):

• On Thursday, February 5th, Glenbrook Capital Management purchased 2,884 shares of Senestech stock. The shares were bought at an average cost of $1.77 per share, with a total value of $5,104.68.
• On Monday, February 2nd, Glenbrook Capital Management acquired 42,739 shares of Senestech stock. The stock was purchased at an average cost of $1.98 per share, for a total transaction of $84,623.22.
• On Friday, January 30th, Glenbrook Capital Management acquired 5,399 shares of Senestech stock. The shares were purchased at an average price of $1.87 per share, for a total transaction of $10,096.13.

Senestech Trading Up 5.1%

Shares of NASDAQ SNES opened at $1.87 on Friday. Senestech, Inc. has a twelve month low of $1.30 and a twelve month high of $6.24. The firm has a market cap of $9.76 million, a PE ratio of -0.51 and a beta of 0.21. The business has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $3.54. The company has a quick ratio of 14.73, a current ratio of 15.75 and a debt-to-equity ratio of 0.01.

Senestech (NASDAQ:SNES) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.07. Senestech had a negative return on equity of 98.35% and a negative net margin of 253.54%.The firm had revenue of $0.69 million for the quarter, compared to analyst estimates of $0.73 million. Analysts expect that Senestech, Inc. will post -10.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Senestech in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Hedge Funds Weigh In On Senestech

A number of large investors have recently added to or reduced their stakes in SNES. Diversify Advisory Services LLC purchased a new stake in shares of Senestech during the fourth quarter valued at about $34,000. Millennium Management LLC purchased a new stake in Senestech during the third quarter valued at approximately $126,000. Sabby Management LLC acquired a new stake in Senestech in the third quarter valued at approximately $313,000. Essex Investment Management Co. LLC purchased a new position in Senestech in the third quarter worth $115,000. Finally, Jane Street Group LLC purchased a new position in Senestech in the second quarter worth $161,000. 5.19% of the stock is currently owned by institutional investors.

Senestech Company Profile

SenesTech, Inc (NASDAQ: SNES) is a biotechnology company specializing in non-lethal pest management solutions. The company’s core focus is the development and commercialization of fertility-based control methods for commensal rodents, providing an alternative to traditional rodenticides. By targeting the reproductive cycle of rats, SenesTech aims to reduce rodent populations over time without the use of toxic chemicals, offering a more sustainable approach for pest management professionals.

The company’s flagship product, ContraPest®, is an EPA-registered liquid bait that disrupts rodent reproduction.